HDL phospholipid: A natural inhibitor of Alzheimer's amyloid β-fibrillogenesis? [2]

Clinical Chemistry and Laboratory Medicine

Volumn 37, Issue 10, 1999, Pages 993-994

  Koudinov, Alexei R ^a,b,c,d   Koudinova, Natalia V ^a,b,d   Berezov, Temirbolat T ^a,b,e   Ivanov, Yurii D ^a  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^b INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^c MENTAL HEALTH RESEARCH CENTER   (Russian Federation)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^e PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN; DIMYRISTOYLPHOSPHATIDYLCHOLINE; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID;

ALZHEIMER DISEASE; COMPETITIVE INHIBITION; HUMAN; LETTER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN SECONDARY STRUCTURE; PROTEOLIPOSOME; RAMAN SPECTROMETRY; SOLUTION AND SOLUBILITY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; CIRCULAR DICHROISM; DIMYRISTOYLPHOSPHATIDYLCHOLINE; HUMANS; LIPOPROTEINS, HDL; NEUROFIBRILS; PROTEIN STRUCTURE, SECONDARY; SPECTRUM ANALYSIS, RAMAN;

EID: 0033408319     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (21)

1. Koudinov A, Koudinova N, Kumar A, Beavis R, Ghiso J. Biochemical characterization of Alzheimer's soluble amyloid beta protein in human cerebrospinal fluid: association with high density lipoproteins. Biochem Biophys Res Commun 1996; 223:592-7.
2. Koudinova N, Koudinov A, Berezov T. Amyloid β in plasma and cerebrospinal fluid is associated with high density lipoproteins. Vopr Med Khim 1996; 42:253-62.
3. Koudinov A, Koudinova N. Soluble amyloid beta protein is secreted by HepG2 cells as an apolipoprotein. Cell Biol Internat 1997; 25:265-71.
4. Koudinov A, Berezov T, Koudinova N. Alzheimer's amyloid beta and lipid metabolism: a missing link? FASEB J 1998; 12:1097-9.
5. Koudinova N, Berezov T, Beavis R, Koudinov A. Purification and characterization of the soluble amyloid beta protein and apolipoproteins from normal cerebrospinal fluid. Biull Eksp Biol Med 1997; 24:425-8.
6. Koudinov A, Berezov T, Kumar A, Koudinova N. Alzheimer's amyloid β interaction with normal human plasma high density lipoprotein: association with apolipoprotein and lipids. Clin Chim Acta 1998; 270:75-84.
7. Shuvaev V, Siest G. Interaction between human amphipathic apolipoproteins and amyloid beta-peptide: surface plasmon resonance studies. FEBS Lett 1996; 383:9-12.
8. Moore M, McCarthy M. Lipid binding and insertion by full-length and truncated Alzheimer's β-amyloid peptides. Biophys J 1994; 66:A384.
9. Kiss R, Kay C, Ryan R. Amphipathic α-helix bundle organization of lipid-free chicken apolipoprotein A-I. Biochemistry 1999; 38:4327-34.
10. Jonas A. Reconstitution of high-density lipoprotein. In: Segrest J, Albers J, editors. Methods in Enzymology. Vol. 129. New York: Academic Press Inc., 1986:120-3.
11. Ivanov Yu, Izotov A, Rukavishnikov I, Uvarov V. Determination of the secondary structure of epoxide hydrolase by Raman spectroscopy. Biochim Biophys Acta 1993; 1162:217-20.
12. Soto C, Castano E, Kumar A, Beavis R, Frangione B. Fibrillogenesis of synthetic amyloid-beta peptides is dependent on their initial secondary structure. Neurosci Lett 1995; 200:105-8.
13. Pappolla M, Bozner P, Soto C, Shao H, Robakis N, Zagorski M, et al. Inhibition of Alzheimer beta-fibrillogenesis by melatonin. J Biol Chem 1998; 273: 7185-8.
14. Koudinov A, Berezov T, Koudinova N. Alzheimer's amyloid beta protein association with high density lipoprotein in normal human cerebrospinal fluid: primary binding to lipid? Soc Neurosci Abst 1997; 23:537.
15. Koudinova N, Kumar A, Berezov T, Koudinov A. Alzheimer's amyloid beta fibrillogenesis: inhibition of apolipoprotein E effect by high density lipoprotein lipid. Neurobiol Aging 1998; 19:1115.
16. Soto C, Sigurdsson E, Morelli L, Kumar A, Castano E, Frangione B. β-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nature Med 1998; 4:822-6.
17. Etienne P, Gauthier S, Dastoor D. Lecithin in Alzheimer's Disease. Lancet 1978; 2:1206.
18. Koudinov A, Matsubara E, Frangione B, Ghiso J. The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma Biochem Biophys Res Commun 1994; 205:1164-71.
19. Ghiso J, Matsubara E, Koudinov A, Choi-Miura N, Tomita M, Wisniewski T, et al. The cerebrospinal fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem J 1993; 293:27-30.
20. Koudinov A, Koudinova N, Berezov T, Uvarov V, Ivanov Yu. Secondary structure of Alzheimer's Aβ1-40 by Raman spectroscopy: effect of proteoliposome. FASEB J 1997; 11:A1005.
21. Koudinov A, Koudinova N, Burbaeva G, Kozirev K, Berezov T, Uvarov V, et al. Alzheimer's amyloid beta secondary structure: effect of high density lipoprotein lipid. Neurosci Lett 1997; 48:S29.